VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | ARROW study: pralsetinib in RET fusion+ tumors

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ARROW study (NCT03037385), which aimed to test the activity of pralsetinib, a selective inhibitor of oncogenic RET alterations in solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter